These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6452690)

  • 1. [In vitro activity of a new cephalosporin--cefoperazone--against Enterobacteriaceae and Pseudomonas aeruginosa].
    Modde H
    Schweiz Med Wochenschr; 1981 Mar; 111(10):356-8. PubMed ID: 6452690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of a new semisynthetic cephalosporin: cefoperazone.
    Auckenthaler R; Waldvogel FA
    Clin Ther; 1980; 3(Spec Issue):89-97. PubMed ID: 6446401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and laboratory evaluation of cefoperazone.
    Sarver DK; Christensen GD; Hester MG; Ling FW; Pate JW; Rosenberg EW; Anderson GD; Bisno AL
    Clin Ther; 1981; 4(3):164-74. PubMed ID: 6458360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro properties of ceftazidime, a highly active broad-spectrum cephalosporin with antipseudomonal activity.
    Harper PB
    Clin Ther; 1984; 6(4):411-24. PubMed ID: 6432324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental efficacy and pharmacokinetic properties of cefpiramide, a new cephalosporin.
    Fu KP; Vince T; McCloud S; Gregory FJ; Chiang ST; Hung PP
    Drugs Exp Clin Res; 1985; 11(11):787-91. PubMed ID: 3939215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Beta-lactamine associations. In vitro synergism and clinical results].
    Acar JF
    Pathol Biol (Paris); 1971; 19(11):593-7. PubMed ID: 4997292
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparison of antibacterial activities of cephalosporins].
    Kayser FH; Kohler ML
    Schweiz Med Wochenschr; 1984 Feb; 114(5):156-61. PubMed ID: 6701496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.
    Wang H; Zhang B; Ni Y; Kuti JL; Chen B; Chen M; Nicolau DP
    Int J Antimicrob Agents; 2007 Nov; 30(5):452-7. PubMed ID: 17646088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative bacteriostatic activity of 10 cephalosporins against 100 strains of Serratia].
    Quentin C; de Barbeyrac B; Savary N; Texier J; Bebear C
    Pathol Biol (Paris); 1983 May; 31(5):379-82. PubMed ID: 6353328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activity of new beta-lactam antibiotics].
    Cullmann W; Stieglitz M
    Fortschr Med; 1982 May; 100(19):888-92. PubMed ID: 6807788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of cefoperazone against clinical isolates of Enterobacteriaceae, Pseudomonas and Staphylococcus.
    Olarte J
    Clin Ther; 1980; 3(Spec Issue):130-3. PubMed ID: 6446386
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibiotic use in neonatal sepsis.
    Yurdakök M
    Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cefoperazone in infections caused by resistant agents, with special reference to Pseudomonas aeruginosa].
    Torres A; Vega J; Aguirre M; Alés JM
    Rev Clin Esp; 1982 Feb; 164(4):229-32. PubMed ID: 6211752
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical use of new cephalosporins for severe infections in internal medicine].
    Stille W
    Wien Klin Wochenschr Suppl; 1983; 142():18-20. PubMed ID: 6316668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates.
    Corser CA; Day GJ; Humble MW
    N Z Med J; 1982 Jun; 95(710):414-6. PubMed ID: 6810246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic properties of the new cephalosporin antibiotic HR810 in laboratory animals.
    Klesel N; Limbert M; Schrinner E; Seeger K; Seibert G; Winkler I
    Infection; 1984; 12(4):286-92. PubMed ID: 6092278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gram-negative bacterial toe web infection: successful treatment with a new third generation cephalosporin.
    Eaglstein NF; Marley WM; Marley NF; Rosenberg EW; Hernandez AD
    J Am Acad Dermatol; 1983 Feb; 8(2):225-8. PubMed ID: 6219139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of cefoperazone in patients after kidney transplantation].
    Wyzgał J; Paczek L; Kozłowska-Boszko B; Mularczyk H
    Pol Tyg Lek; 1990 Oct 1-8; 45(40-41):815-6. PubMed ID: 2128960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.